Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lifts Close Brothers target as regulatory risks reduce

(Sharecast News) - Shares in Close Brothers Group continued to surge on Wednesday after the merchant bank's first-half results in which the company eased investors' concerns about an upcoming regulatory probe, with Berenberg providing an extra boost after lifting its target price for the stock. The stock was up 8.5% at 376.64p by 1106 GMT, following a 2.9% jump the previous session after the company announced a raft of measures - including the suspension of dividends - to strengthen its capital position by £400m as it prepares for the conclusion of a Financial Conduct Authority investigation into motor finance, which centres around so-called discretionary commission arrangements. Through DCAs, lenders allowed motor dealers to use their discretion to land on interest rates within a certain range, leading to claims that consumers had been over-charged for car loans between 2007 and 2021.

Berenberg said that actions, which could provide around 390 basis points of capital support, "help to alleviate risks to the bank's potential large and uncertain motor finance redress costs".

The broker added: "While uncertainty remains high, with the bank's share price still down c55% ytd, growth in Close Brothers' core businesses is also reassuringly resilient."

Berenberg upped its target price from 425p to 470p, saying it now values the bank at 0.4 times tangible book value, up from 0.3 times currently.

"We maintain our 'buy' rating, but acknowledge risks may be too great to bear for many investors."

Share this article

Related Sharecast Articles

Biome Technologies shares sink as Q1 sales drop 44%
(Sharecast News) - Shares in AIM-listed Biome Technologies plummeted by almost a third on Monday after the bioplastics and radio frequency technology business reported a poor start to the year with first-quarter sales dropping by 44%.
Entain reprices two term loans, revises interest cost outlook
(Sharecast News) - Betting and gambling giant Entain announced the successful repricing of two of its existing 'Term Loan B' loans on Monday, along with the pricing and allocation of fungible add-ons, in a bid to optimise its financial position.
Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.